Navigation Links
New research to revolutionize healthcare through remote monitoring of patients
Date:2/27/2014

Researchers from the University of Surrey have today launched a new programme of research called eSMART (Electronic Symptom Management using ASyMS Remote Technology), that uses mobile phone technology to remotely monitor patients who are undergoing chemotherapy to treat breast, bowel and blood cancers.

The Advanced Symptom Management System (ASyMS) allows patients to report the side effects from their chemotherapy via a mobile phone. This information is immediately sent securely to a computer, which assesses their symptoms and triggers alerts to doctors or nurses within minutes if they require specialist intervention.

The system also provides patients with real-time information and advice on how to manage their symptoms at home, without the need to travel to hospital.

Researchers believe that using ASyMS will reduce the side effects of chemotherapy, and help to identify and treat those which are life-threatening much quicker than current care systems. In addition, it is anticipated that the use of ASyMS will significantly reduce healthcare costs.

A 6 million grant from the European Union will fund a large 1,000 patient trial in England, Austria, Greece, Holland, Ireland and Norway, with the hope that the new system will be integrated into routine cancer care in the future. The research team is also developing and testing the system for use by people with other types of cancer and long-term conditions such as heart failure.

"Over 3 million people are diagnosed with cancer each year in Europe and it is likely that this number will increase by at least 65% over the next 20 years," said Nora Kearney, Professor of Cancer Care at the University of Surrey and Principal Investigator.

"Given this predicted increase, the need for personalised cancer care is becoming even more crucial. Our system will give patients continual support both during and after chemotherapy, while allowing them to remain in the comfort of their own homes. It will revolutionise the way our healthcare system supports people with cancer."

Kathi Apostolidis, Vice President of The European Cancer Patient Coalition (ECPC) one of the partners on the eSMART project, said: "In many European countries, patients undergoing chemotherapy, experience great difficulties in coping with the adverse events and the anxiety during their therapy and between treatments.

"Usually, patients with cancer are given instructions on how to cope with side effects, at the beginning of their treatment. However, in many European countries, it is not possible, or very difficult for patients to consult their oncologist or oncology nurse to discuss problems or concerns arising from their chemotherapy, outside pre-arranged medical appointments. ECPC believes that eSMART will be an urgently needed solution to get a quick response to the problems and anxiety that cancer patients face during chemotherapy."


'/>"/>
Contact: Peter La
p.la@surrey.ac.uk
01-483-689-191
University of Surrey
Source:Eurekalert

Related medicine news :

1. 3-D microgels on-demand offer new potential for cell research
2. Fox Chase researchers discover new mechanism of gene regulation
3. Research maze puts images on floor, where rodents look
4. Research links risky behaviors of gambling and sex
5. Penn researchers show nuclear stiffness keeps stem cells and cancer cells in place
6. CWRU researchers find byproducts of bacteria-causing gum disease incite oral cancer growth
7. Researchers make the invisible visible
8. GW researcher finds gene therapy a promising tool for cardiac regeneration
9. MD Anderson researcher uncovers some of the ancient mysteries of leprosy
10. Researchers look for culprit behind oral health problems in HIV-positive patients
11. American Heart Association awards Loyola $438,740 for cardiac research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in wound care advancements to physician colleagues, skilled nursing facility medical directors and ... the Treacherous Waters of Wound Care." , "At many of these conferences we ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/13/2017)... 13, 2017   OrthoAtlanta has been named the ... Host Committee (AFHC) for the 2018 College Football Playoff (CFP) ... at Mercedes-Benz Stadium in Atlanta, Georgia . ... "I,m In" campaign, participating in many activities leading up to, ... ...
Breaking Medicine Technology: